Prognosis comparison between surgical treatment and transcatheter arterial chemoembolization combined with sorafenib in patients with advanced hepatocellular carcinoma
10.3760/cma.j.issn.1006-9801.2013.08.011
- VernacularTitle:索拉非尼联合手术或联合经导管肝动脉栓塞化疗治疗进展期肝癌的预后比较
- Author:
Liqun WU
;
Zixiang LI
;
Jun LIANG
- Publication Type:Journal Article
- Keywords:
Neoplasms,hepatocellular;
Sorafenib;
Prognosis;
Surgery;
Transcatheter arterial chemoembolization
- From:
Cancer Research and Clinic
2013;25(8):543-546
- CountryChina
- Language:Chinese
-
Abstract:
Objective To investigate the prognostic factors of sorafenib treatment in patients with advanced hepatocellular carcinoma (HCC) underwent surgical therapy or transcatheter arterial chemoembolization (TACE).Methods 62 patients with advanced HCC underwent surgical therapy or TACE were post-treated with sorafenib (400mg,bid).The overall survival (OS) and progress-free survival (PFS) were evaluated by Kaplan-Meier method.Results There were 30 patients in surgical group and 32 patients in TACE group.The median OS in surgical group and TACE group were 12.2 and 5.7 months (P =0.019) and the median PFS were 16.7 and 10.6 months (P =0.033),respectively.The liver cancer volume / liver volume ＞50 ％ and Child-Pugh classification were independent risk factors for PFS in surgical group,the Child-Pugh classification and vascular invasion were independent risk factors for OS in surgical group.Conclusion The patients' PFS and OS in surgical group by oral sorafenib are better than those of patients in TACE group.The effective ways to prolong the PFS include decreasing volume of liver cancer and the better liver function.
